04.02.2013 Views

official journal of the patent office - Controller General of Patents ...

official journal of the patent office - Controller General of Patents ...

official journal of the patent office - Controller General of Patents ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

(12)<br />

(19)<br />

(22)<br />

PATENT APPLICATION PUBLICATION<br />

INDIA<br />

Date <strong>of</strong> filing <strong>of</strong> Application: 07/01/2005<br />

(21)<br />

(43)<br />

Application No.: 68/DEL NP/2005<br />

Publication Date:09/06/2006<br />

(54) Title <strong>of</strong> <strong>the</strong> Invention: “Produrg, Medicinal utilization <strong>the</strong>re<strong>of</strong> and process for producing <strong>the</strong> same.”<br />

(51) International Classification : C07H 15/303<br />

(31) Priority Document No. : 2002/180238<br />

(32) Priority Date : 20/06/2002<br />

(33) Name <strong>of</strong> priority country Japan<br />

(86) International application No. : PCT/JP03/007868<br />

Filing Date : 20/06/2003<br />

(87) International Publication No. : WO/2004/000863<br />

(61) Patent <strong>of</strong> Addition to<br />

Application No.<br />

: N.A.<br />

(62) Divisional to Application No. : NIL<br />

Filed On : N.A.<br />

Total No. <strong>of</strong> pages : 58+07=65<br />

(71) Name <strong>of</strong> Applicant :<br />

NIPPON SUISAN KAISHA, LTD.<br />

Address <strong>of</strong> <strong>the</strong> Applicant: 2-6-2, Ohtemachi,<br />

Chiyoda-ku, , Tokyo 100-0004 (JP)<br />

(72) Name <strong>of</strong> <strong>the</strong> Inventor:<br />

YAMASHITA Shinya,<br />

TAKEO Jiro,<br />

OKITA Takaaki,<br />

(57) Abstract: A prodrug utilizes an enzyme whose enzymatic activity is different in between <strong>the</strong> target site <strong>of</strong> <strong>the</strong><br />

drug and <strong>the</strong> site to express side effects, <strong>the</strong> prodrug having a substituent cleavable with <strong>the</strong> enzyme and being<br />

activated by cleaving <strong>the</strong> substitutent with <strong>the</strong> enzyme. As <strong>the</strong> target site <strong>of</strong> <strong>the</strong> drug, for example, a respiratory organ<br />

can be mentioned and as <strong>the</strong> site to express side effects, for example, <strong>the</strong> heart can be mentioned and as <strong>the</strong><br />

example <strong>of</strong> <strong>the</strong> enzyme, a glycosidase (for example,ß-glucuronidase) can be mentioned. Fur<strong>the</strong>rmore, <strong>the</strong><br />

substituent is, for example, a glycosy1 group composed <strong>of</strong> a monosaccharide or an oligosaccharide. Use <strong>of</strong> <strong>the</strong><br />

enzyme enables reducing <strong>the</strong> side effects <strong>of</strong> a drug <strong>of</strong> <strong>the</strong> type whose target site is different from <strong>the</strong> site to express<br />

side effects.<br />

The Patent Office Journal 09/06/2006 11112<br />

A

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!